Status
Not yet recruiting
Phase
Phase 2
Enrollment
75
Locations
1
Results
Not posted
Publications
0
Study summary
This study is testing whether oxytocin can help lessen pain by changing how people process emotions and social experiences. The goal is to better understand how the brain links emotions, relationships, and pain, and whether this connection can be used to improve pain treatment.
This study employs a randomized, double-blind, placebo-controlled design to evaluate the efficacy of an intranasal oxytocin formulation, TNX-1900, on pain management, neural functioning, and socio-emotional health in patients undergoing pituitary surgery. Participants will be randomized into 3 groups: One group will receive low-dose oxytocin (6 IU), one group will receive high-dose oxytocin (24 IU), and one group will receive a matching placebo formulation. Participants will administer their nasal spray (blinded) daily for 7 days leading up to, and including the day of surgery, and 7 days following the surgery. Assessments (surveys and EEG/ERP) will be included throughout the protocol.
Interventions
DRUG
The dosage for low -dose intranasal oxytocin is set at 6 International Units (IU) per day, divided into two administrations of 3IU each per nostril. The administration begins one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.
DRUG
The dosage for high-dose intranasal oxytocin is set at 24 International Units (IU) per day, divided into two administrations of 12 IU each per nostril. The administration begins one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.
DRUG
Placebo nasal spray (no study medication, magnesium only). The administration begins one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.
Timeline
First posted
Jul 28, 2026
Study start
Aug 2026
Primary completion
Aug 2028
Study completion
Aug 2028
Results posted
Not reported
Registry updated
Jul 28, 2026
Outcomes
Change in post-operative pain measured by the Numeric Pain Rating Scale (NPRS)
Time frame · Pre-op up to 8 weeks after last drug administration
The NPRS is a patient-reported tool used to assess pain intensity on a scale from 0 (no pain) to 10 (worst possible pain).
Change in post-operative pain measured by monitoring of pain medication usage
Time frame · Pre-op up to 8 weeks after last drug administration
Daily pain medication usage will be reported by participants leading up to surgery and after discharge. Daily pain medication usage will be reported through the participant's medical record during surgery and inpatient stay.
Changes in participant reported depression as measured by the Beck Depression Inventory (BDI-II)
Time frame · Pre-op up to 8 weeks after last drug administration
BDI-II is a 21-item patient-reported questionnaire used to assess the severity of depressive symptoms. Total scores range from 0 to 63, with higher scores indicating more severe depression.
Changes in participant reported anxiety as measured by the Beck Anxiety Inventory (BAI)
Time frame · Pre-op up to 8 weeks after last drug administration
BAI is a 21-item patient-reported questionnaire used to assess the severity of anxiety symptoms. Total scores range from 0 to 63, with higher scores indicating more severe anxiety.
Changes in participant reported anxiety as measured by the Generalized Anxiety Disorder-7
Time frame · Pre-op up to 8 weeks after last drug administration
GAD-7 is a 7-item patient-reported questionnaire used to assess the severity of anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating more severe anxiety.
Changes in participant reported depression as measured by the Patient Health Questionnaire-9
Time frame · Pre-op up to 8 weeks after last drug administration
PHQ-9 is a 9-item patient-reported questionnaire used to assess the severity of depressive symptoms. Total scores range from 0 to 27, with higher scores indicating more severe depression.
Change in neural functioning measured by Electroencephalography (EEG)/Event-Related Potential (ERP)
Time frame · Pre-op and the last day of drug administration, approximately 14 days
EEG/ERP sessions are done at specific intervals to look at delta-beta neural oscillations and N170, P300, and LPP ERPs elicited by social and emotional stimuli (photos of faces and houses).
Eligibility
Inclusion Criteria: * Age: Between 30 to 75 years old. * Consent: Ability to give informed consent. * Language: Proficiency in the English language. * Medical Condition: Diagnosed with a pituitary lesion requiring surgery. * Menopausal Status: Post-menopause for women (at least 1 year since last menstrual period). Exclusion Criteria: * Medication: Individuals on stable doses of psychotropic medication for at least the past six weeks are eligible, excluding those with changes in medication within that timeframe. * Neurological Conditions: A history of seizures, current use of anticonvulsants. * Pregnancy: Currently pregnant, currently lactating, or up to 1-year post partum. * Any history of renal impairment (serum creatinine \>1.2 x ULN) * Any history of hepatic impairment (AST and/or ALT \>2 x ULN) * Surgical History: Any history of previous pituitary surgery procedures * Subjects who require 24-hour coverage with NSAIDs, e.g., arthritis, should not be included in the study. * Any known hypersensitivity to TNX-1900
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Yale University
New Haven, Connecticut, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Wake Forest University Health Sciences · Total Hip Arthroplasty
Phase 2
Enrolling by invitation
80
2026-07
Medical University of South Carolina · PTSD · Alcohol Use Disorder
Phase 2
Completed
175
2026-07
University Hospital, Tours · Cervical Ripening · Unfavorable Cervix
Phase 3
Recruiting
1,494
2026-07
Icahn School of Medicine at Mount Sinai · Pregnancy · Labor
Phase 3
Recruiting
281
2026-07
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Aalto University · Induction of Birth · Cervical Ripening
Not applicable
Recruiting
40
2026-07
Ochsner Health System · Nulliparous Women Who Scheduled for Labor Induction · Pregnancy
Not applicable
Not yet recruiting
260
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.